Navigation Links
Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
Date:10/12/2010

MORRISTOWN, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its third quarter 2010 financial results on Thursday, November 4, 2010 prior to the open of the U.S. financial markets.  The Company will also host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on November 4, 2010 to discuss its financial results and provide an update on the Company's outlook for 2010.  The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Daylight Time on November 14, 2010.  The replay may be accessed by dialing (800) 642-1687 and entering pass code 14461923.  From international locations, the replay may be accessed by dialing (706) 645-9291 and entering the same pass code.  To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.  A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit the Watson Web site at http://www.watson.comCONTACTS:Investors:Patty EisenhaurWatson Pharmaceuticals, Inc.(973) 355-8141Media:Charlie MayrWatson Pharmaceuticals, Inc. (973) 355-8483(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... skills and infrastructure. Most providers, however, are unsure how to move forward, given ... to define a path forward tailored to an organization’s specific needs. , ...
(Date:6/24/2016)... ... 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to 75 ... sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The Medicine ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
Breaking Medicine News(10 mins):